loader image
Thursday, October 30, 2025
66.4 F
McAllen
- Advertisement -

Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune System

Translate to Spanish or other 102 languages!

DHR Health Institute for Research and Development is currently offering long-acting monoclonal antibody treatment to PREVENT COVID-19 in high-risk patients. Image for illustration purposes.
DHR Health Institute for Research and Development is currently offering long-acting monoclonal antibody treatment to PREVENT COVID-19 in high-risk patients. Image for illustration purposes.

Mega Doctor News

- Advertisement -

EDINBURG, TX – DHR Health Institute for Research and Development is currently offering long-acting monoclonal antibody treatment to PREVENT COVID-19 in high-risk patients. This is the only treatment currently available to prevent infection by the Omicron variant of SARS-CoV-2…the virus that causes COVID-19.

On December 8, 2021, the U.S. Food and Drug Administration issued an Emergency Use Authorization allowing the use of AstraZeneca’s long-acting antibody EVUSHELDTM to be used for prevention of COVID-19 in subjects 12 years and older with moderate to severe immunocompromised status before exposure to the virus.

“The majority of the patients who are currently hospitalized with severe COVID-19 are those who are unvaccinated, and those who are vaccinated, but have a compromised immune system” said Sohail Rao, MD, MA, DPhil, President and CEO, DHR Health Institute for Research & Development. “Given that Omicron is the dominant variant which is responsible for the current spike in COVID-19 cases in the US and globally, EVUSHELDTM is the only antibody that can offer long-term protection against this variant in patients with weakened immune system”

- Advertisement -

I

Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune SystemTreatment with this long-acting antibody will provide patients with protection against SARS-CoV-2 (including its Omicron variant) for up to 6-9 months. In the last few weeks, we have treated over 50 patients at DHR Health with this monoclonal antibody with a very satisfactory outcome.

If you or your patient is interested to receive this treatment or need to discuss their condition further, please call 956-342-4896 or download the contact information by using this QR Code: 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Pharmacists Help Cancer Patients Manage High Blood Sugar More Effectively

Mega Doctor News By University of California San Diego Newswise — People with cancer...

Renaissance Cancer Foundation’s 15th Anniversary Gala Event, Nov. 15th

The Renaissance Cancer Foundation, a non-profit organization with DHR Health, is excited to announce its 15th Anniversary Gala, featuring the Miami sounds of music group, The Clique. The event is set to take place on November 15, 2025 at the Edinburg Conference Center at Renaissance, located at 118 Paseo Del Prado in Edinburg.

Mayo Clinic Study Finds Majority of Midlife Women with Menopause Symptoms Do Not Seek Care

A new study from Mayo Clinic underscores the widespread impact of menopause symptoms on midlife women — and raises concern that most are navigating this stage of life without medical care to help manage those challenges.

Research Reveals Genetic Link to Most Common Pediatric Bone Cancer

Researchers at Cleveland Clinic Children’s have helped identify a gene that increases the risk of developing osteosarcoma, which is the most common type of bone cancer in children and young adults. 
- Advertisement -
×